Anti-VEGF therapy appears effective in patients with pseudoxanthoma elasticum

This case series included nine eyes with pseudoxanthoma elasticum and choroidal neovascularization treated with either bevacizumab 1.25 mg/0.05 mL or ranibizumab 0.5 mg/0.05 mL. During a mean follow-up period of 28.6 months, visual acuity either improved or stabilized in all nine eyes. Mean visual acuity improved from 20/368 to 20/281. Serial optical coherence tomography measurements showed mean lesion height decreased from 353 µm at baseline to 146 µm at the last visit (P =0.005). Patients received an average of 8.4 injections. No complications were noted.